Intelligence Platform

Patents

Browse 14,889 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11786548

Trace element compositions, methods of making and use

American Regent, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11787840

Compositions and methods for treating and preventing autoimmune induced cardiac long QT sy

United States Government as represented by the Department of Veterans Affairs · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786488

Dosage forms and methods for enantiomerically enriched or pure bupropion

AXSOME THERAPEUTICS, INC. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786508

Use of sublingual dexmedetomidine for the treatment of agitation

BioXcel Therapeutics, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786540

Gliflozins and a method for their delivery during resuscitation from cardiac arrest to imp

THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786517

Methods of treatment using a JAK inhibitor compound

Theravance Biopharma R&D IP, LLC · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786486

Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dion

PTC THERAPEUTICS, INC. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11787869

Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject hav

Dyne Therapeutics, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786518

Ophthalmic formulations and uses thereof

Aldeyra Therapeutics, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786546

Compounds and methods for modulating GFAP

Ionis Pharmaceuticals, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786464

PH responsive block copolymer compositions and micelles that inhibit MCT 1 and related pro

The Board of Regents of the University of Texas System · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786503

Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity

Auransa Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786582

Human application of engineered chimeric antigen receptor (CAR) T-cells

granted patent

US 11786597

Ionic liquids for transdermal drug delivery

The Regents of the University of California · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11788077

Polynucleotides encoding optimized engineered meganucleases having specificity for a recog

Precision BioSciences, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786541

Inhibitor of sphingosine kinase 2 for treating Ebola

RedHill Biopharma Ltd. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11787762

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

Arcus Biosciences, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11787778

Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

Montelino Therapeutics Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786542

Methods for enhancing cytotoxic cancer therapy through modulation of purine biosynthesis p

Northwestern University · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11787804

Compositions and methods for modulating hair growth

The Regents of the University of California · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11781110

Induction of corneal endothelial cells

The Regents of the University of California · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11781143

Modulators of PNPLA3 expression

Ionis Pharmaceuticals, Inc. · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11781156

Plakophillin-2 gene therapy methods and compositions

Tenaya Therapeutics, Inc. · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11780931

CD47 targeted therapies for the treatment of infectious disease

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted